Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22322| Title: | Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush? | Austin Authors: | Arulananda, Surein;John, Thomas | Affiliation: | Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Heidelberg, Australia Department of Medical Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia |
Issue Date: | Jan-2020 | Publication information: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020; 15(1): 12-14 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/22322 | DOI: | 10.1016/j.jtho.2019.10.017 | ORCID: | 0000-0002-5636-6381 | Journal: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | PubMed URL: | 31864546 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.